chufangao/CTO huggingface dataset:
Clinical trial NCT03470350: Galunisertib and Capecitabine in Advanced Resistant TGF-beta Activated Colorectal Cancer
Official title: MoTriColor: Phase I/II Study With Galunisertib (LY2157299) Combined With Capecitabine in Patients With Advanced Chemotherapy Resistant Colorectal Cancer and an Activated TGF-beta Signature
Acronym: EORTC1615
Sponsor: The Netherlands Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: WITHDRAWN 
Why stopped: No study drug available. Same concept with new study drug will be explored in M19TGA study
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-08-24
Primary completion date: 2020-06-01
Completion date: 2020-06-01
Plan to share individual participant data: NO
Clinical trial NCT01760525: A Phase I Dose Escalation Study of CGM097 in Adult Patients With Selected Advanced Solid Tumors
Official title: A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral CGM097, a p53/HDM2-interaction Inhibitor, in Adult Patients With Selected Advanced Solid Tumors
Acronym: CCGM097X2101
Sponsor: Novartis (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 51.0 (ACTUAL)
Number of arms: 2.0
Start date: 2013-03-20
Primary completion date: 2020-07-24
Completion date: 2020-07-24
Plan to share individual participant data: NO
Clinical trial NCT04457336: A Ph2b to Evaluate Clinical Efficacy and Safety of Tildacerfont in Adult CAH
Official title: A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects With Classic Congenital Adrenal Hyperplasia
Sponsor: Spruce Biosciences (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study SPR001-203 did not meet its primary and secondary endpoints therefore Spruce Biosciences has decided to terminate the study
Enrollment: 96.0 (ACTUAL)
Number of arms: 4.0
Start date: 2020-08-26
Primary completion date: 2024-02-09
Completion date: 2024-05-23
Plan to share individual participant data: NO
Clinical trial NCT02487953: Electronic Nicotine Delivery Systems as a Smoking Cessation Treatment
Official title: Electronic Nicotine Delivery Systems (ENDS) as a Smoking Cessation Treatment
Acronym: ENDS-P50
Sponsor: Duke University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Study design changed significantly; was submitted as a different protocol.
Enrollment: 0.0 (ACTUAL)
Number of arms: 3.0
Start date: 2018-07-31
Primary completion date: 2020-01-31
Completion date: 2022-01-31
Clinical trial NCT04972123: The Effect of CPC on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope
Official title: The Effect of Capsaicin-Phenylephrine-Caffeine Formulation on Aborting Tilt Induced Syncope in Patients With a History of Vasovagal Syncope or Near Syncope
Sponsor: University of Wisconsin, Madison (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 143.0 (ACTUAL)
Number of arms: 2.0
Start date: 2021-07-20
Primary completion date: 2023-08-25
Completion date: 2023-08-31
Baseline population: Evaluable participants for intention to treat primary endpoint By protocol entry criteria the age range was 18 to 50 Years.
Plan to share individual participant data: NO
Clinical trial NCT03937141: Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Head and Neck Cancer
Official title: A Phase 2 Efficacy and Safety Trial of ADU-S100 and Pembrolizumab in Adults With Head and Neck Cancer
Sponsor: Chinook Therapeutics, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: No substantial anti-tumor activity was observed.
Enrollment: 16.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-08-26
Primary completion date: 2021-05-10
Completion date: 2021-06-10
Baseline population: All participants who received at least one dose of study drug.
Clinical trial NCT01395641: A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC
Official title: A Phase I/II Clinical Trial for Treatment of Aromatic L-amino Acid Decarboxylase (AADC) Deficiency Using AAV2-hAADC
Acronym: AADC
Sponsor: National Taiwan University Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE1/PHASE2
Status: COMPLETED 
Enrollment: 10.0 (ACTUAL)
Number of arms: 1.0
Start date: 2014-10-22
Primary completion date: 2020-12-18
Completion date: 2022-03-07
Clinical trial NCT03825341: Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere
Official title: Hydroxyurea Therapy: Optimizing Access in Pediatric Populations Everywhere
Sponsor: St. Jude Children's Research Hospital (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The study terminated early due to challenges with recruitment during the COVID pandemic.
Enrollment: 1.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-06-10
Primary completion date: 2022-01-20
Completion date: 2022-01-20
Baseline population: No enrollments on Arm 1.
Limitations and caveats: No participants were treated on this study.
Plan to share individual participant data: YES
IPD sharing description: Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.
IPD time frame: Data will be made available at the time of article publication.
IPD access criteria: Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.
Clinical trial NCT04307186: Study to Find the Appropriate Dose of a New Gadolinium-based Contrast Agent (GBCA) for Adults Undergoing Magnetic Resonance Imaging (MRI) for Known or Highly Suspected Brain and/or Spinal Cord Conditions
Official title: Multicenter, Single-blind, Adaptive Dose Finding Study of Single Intravenous Injections of BAY 1747846 With Corresponding Blinded Read in Adult Participants With Known or Highly Suspected CNS Lesions Referred for Contrast-enhanced MRI of the CNS
Sponsor: Bayer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 57.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-11-18
Primary completion date: 2022-09-05
Completion date: 2022-09-06
Plan to share individual participant data: NO
IPD sharing description: Availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA Principles for responsible clinical trial data sharing. This pertains to scope, timepoint and process of data access. As such, Bayer commits to sharing upon request from qualified researchers patient-level clinical trial data, study-level clinical trial data, and protocols from clinical trials in patients for medicines and indications approved in the US and EU as necessary for conducting legitimate research. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014.~Interested researchers can use www.vivli.org to request access to anonymized patient-level data and supporting documents from clinical studies to conduct research. Information on the Bayer criteria for listing studies and other relevant information is provided in the member section of the portal.
Clinical trial NCT03867162: FY15-14: Tularemia Vaccine Protocol (NDBR Lot 4)
Official title: Phase 2 Open-Label Safety and Immunogenicity Study of Tularemia Vaccine, Live, Attenuated (NDBR 101, Lot 4) in Adult Subjects at Risk of Exposure to Tularemia Bacteria
Acronym: NDBR
Sponsor: U.S. Army Medical Research and Development Command (FED)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: WITHDRAWN 
Why stopped: Sponsor terminated this protocol on Dec17, 2021; no subjects have been enrolled
Enrollment: 0.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-06-09
Primary completion date: 2021-12-17
Completion date: 2021-12-17
Plan to share individual participant data: NO
Clinical trial NCT02807883: Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
Official title: Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia
Sponsor: M.D. Anderson Cancer Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2016-08-31
Primary completion date: 2022-02-01
Completion date: 2022-02-01
Clinical trial NCT04076462: A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly
Official title: A Phase 3, Randomized, Double-blind, Placebo-controlled, Multi-center Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With Acromegaly
Acronym: ACROINNOVA 1
Sponsor: Camurus AB (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 72.0 (ACTUAL)
Number of arms: 2.0
Start date: 2019-08-19
Primary completion date: 2023-05-02
Completion date: 2023-05-02
Plan to share individual participant data: NO
Clinical trial NCT04500418: Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients
Official title: Charité Trial of Cenicriviroc (CVC) Treatment for COVID-19 Patients
Sponsor: Charite University, Berlin, Germany (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Despite multiple efforts, no further patient could be enrolled since 03/05/2021. A continuation of the study is therefore no longer justified
Enrollment: 45.0 (ACTUAL)
Number of arms: 2.0
Start date: 2020-08-25
Primary completion date: 2021-07-27
Completion date: 2021-07-27
Plan to share individual participant data: UNDECIDED
IPD sharing description: Undecided at this moment. (08/2020)
Clinical trial NCT04594707: A Study to Evaluate Long Term Safety and Efficacy of Recombinant Human Pentraxin-2 (rhPTX-2; PRM-151) in Participants With Idiopathic Pulmonary Fibrosis
Official title: A Phase III Open-label Extension Study to Evaluate Long-term Safety and Efficacy of PRM-151 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Acronym: STARSCAPE-OLE
Sponsor: Hoffmann-La Roche (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: The study was terminated by Sponsor as the futility analysis outcome indicated that the study was unlikely to meet the predefined primary objective of the study. No new safety concerns were identified.
Enrollment: 117.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-08-30
Primary completion date: 2023-02-10
Completion date: 2023-02-10
Limitations and caveats: This study was terminated early due to the Sponsor's decision to terminate the parent study early.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Clinical trial NCT02352948: A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer
Official title: A Phase III, Open Label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC).
Acronym: ARCTIC
Sponsor: AstraZeneca (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: COMPLETED 
Enrollment: 597.0 (ACTUAL)
Number of arms: 6.0
Start date: 2015-01-13
Primary completion date: 2018-02-09
Completion date: 2023-08-30
Baseline population: Sub-study A and B: Full analysis set (FAS) included all randomized participants analyzed on an intent-to-treat (ITT) basis.
Plan to share individual participant data: YES
IPD sharing description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
IPD access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure
Clinical trial NCT03947255: A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma
Official title: A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)
Sponsor: Seagen Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Study stopped early due to low patient accrual.
Enrollment: 12.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-10-28
Primary completion date: 2022-11-06
Completion date: 2022-11-06
Baseline population: The full analysis set includes participants who received at least one dose of study treatment.
Clinical trial NCT04843579: Treatment of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone for Relapsed Refractory Multiple Myeloma Patients
Official title: A Phase 2, Open-Label, Single-Arm Study of Selinexor in Combination With Clarithromycin, Pomalidomide and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma
Acronym: ClaSPd
Sponsor: Weill Medical College of Cornell University (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: low enrollment
Enrollment: 4.0 (ACTUAL)
Number of arms: 1.0
Start date: 2021-12-29
Primary completion date: 2022-11-30
Completion date: 2022-12-30
Limitations and caveats: The statistical analysis plan (and associated statistical power) was based on an expected sample size of 26 participants. As only 4 participants enrolled, this reduced sample size was not sufficient for the statistical analysis plan as written, and, therefore, only descriptive statistics for the response proportions can be presented for the study.
Plan to share individual participant data: NO
Clinical trial NCT03300544: Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
Official title: A Phase I Study of Talimogene Laherparepvec (Talimogene Laherparepvec) With Neoadjuvant Chemotherapy and Radiation in Adenocarcinoma of the Rectum
Sponsor: National Cancer Institute (NCI) (NIH)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: Inadequate accrual rate
Enrollment: 3.0 (ACTUAL)
Number of arms: 1.0
Start date: 2019-05-14
Primary completion date: 2022-03-22
Completion date: 2022-03-22
Clinical trial NCT03698448: A Dose-finding Study of Inhaled OligoG vs Placebo in Patients With Cystic Fibrosis
Official title: A Randomized, Double Blind, Dose-finding Study of Inhaled Oligosaccharide (OligoG) vs Placebo in Patients With Cystic Fibrosis
Acronym: SMR3372
Sponsor: AlgiPharma AS (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2/PHASE3
Status: WITHDRAWN 
Why stopped: Determined not feasible
Enrollment: 0.0 (ACTUAL)
Number of arms: 4.0
Start date: 2021-09-01
Primary completion date: 2022-10-01
Completion date: 2022-11-01
Plan to share individual participant data: NO
Clinical trial NCT04511624: Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects
Official title: A Phase I Randomized, Double-Blind, Placebo-Controlled, Single Subcutaneous or Intravenous Ascending Dose Trial to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IBI112 in Healthy Subjects
Sponsor: Innovent Biologics (Suzhou) Co. Ltd. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: COMPLETED 
Enrollment: 46.0 (ACTUAL)
Number of arms: 7.0
Start date: 2020-08-27
Primary completion date: 2022-07-22
Completion date: 2022-07-22
Clinical trial NCT04425538: A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).
Official title: A Phase 2 Trial of Infliximab in Coronavirus Disease 2019 (COVID-19).
Sponsor: Tufts Medical Center (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: COMPLETED 
Enrollment: 17.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-06-01
Primary completion date: 2021-01-22
Completion date: 2021-01-22
Plan to share individual participant data: NO
Clinical trial NCT04763564: Efficacy of Liraglutide Therapy in Patients With IPAA
Official title: Efficacy of Liraglutide Therapy in Patients With an Ileal -Pouch Anal Anastomosis (IPAA) and Chronic High Bowel Frequency
Sponsor: University of North Carolina, Chapel Hill (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Due to an interruption in drug supply, the study was terminated
Enrollment: 8.0 (ACTUAL)
Number of arms: 2.0
Start date: 2022-03-22
Primary completion date: 2023-10-16
Completion date: 2023-10-16
Limitations and caveats: Small cross-over proof of concept study. The findings need to be verified in a more extensive prospective randomized study.
Plan to share individual participant data: YES
IPD sharing description: Deidentified individual data that supports the results will be shared beginning 3 to 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with the University of North Carolina \[UNC\].
IPD time frame: Beginning 3 months and ending 36 months following article publication.
IPD access criteria: Researchers who provide a methodologically sound proposal.
Clinical trial NCT04645966: A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants
Official title: A PHASE 2b TRIAL TO ASSESS THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF MenABCWY IN HEALTHY INFANTS 2 AND 6 MONTHS OF AGE
Sponsor: Pfizer (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: The Sponsor decided to discontinue the study based on Sponsor's careful review of available safety data in concert with the recommendation of an independent Data Monitoring Committee.
Enrollment: 326.0 (ACTUAL)
Number of arms: 11.0
Start date: 2020-11-26
Primary completion date: 2022-09-15
Completion date: 2022-09-15
Baseline population: Safety population included all randomized participants who received at least 1 dose of investigational product and had safety data reported after vaccination.
Limitations and caveats: Study was terminated based on Sponsor's careful review of available safety data in concert with the recommendation of an independent Data Monitoring Committee.
Plan to share individual participant data: YES
IPD sharing description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Clinical trial NCT02826512: A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients
Official title: A Feasibility Study of Niraparib for Advanced, BRCA1-like, HER2-negative Breast Cancer Patients: the ABC Study
Sponsor: The Netherlands Cancer Institute (OTHER)
Study type: INTERVENTIONAL
Phase: PHASE2
Status: TERMINATED 
Why stopped: Not enough eligble patient can be found, too many screen failures
Enrollment: 9.0 (ACTUAL)
Number of arms: 1.0
Start date: 2018-05-15
Primary completion date: 2022-07-01
Completion date: 2022-07-01
Plan to share individual participant data: UNDECIDED
IPD sharing description: to be determined
Clinical trial NCT02562443: Controlled Study of Rigosertib Versus Physician's Choice of Treatment in MDS Patients After Failure of an HMA
Official title: A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Acronym: INSPIRE
Sponsor: Traws Pharma, Inc. (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE3
Status: TERMINATED 
Why stopped: Top line analysis indicated that the study had failed to achieve its primary endpoint.
Enrollment: 372.0 (ACTUAL)
Number of arms: 2.0
Start date: 2015-12-02
Primary completion date: 2020-07-26
Completion date: 2021-07-26
Clinical trial NCT03256331: Evaluate the Safety of BEL-X-HG in Advanced Cancer Patients
Official title: A Phase I, Open-Label, Dose Escalation and Extension Study to Evaluate the Safety, Tolerability and Preliminary Effects of Oral BEL-X-HG in Patients With Advanced Refractory Solid Malignancies
Sponsor: Belx Bio-Pharmaceutical (Taiwan) Corporation (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE1
Status: TERMINATED 
Why stopped: In the light of the on-going COVID-19 pandemic and the resulted difficulty in patient recruitment.
Enrollment: 23.0 (ACTUAL)
Number of arms: 1.0
Start date: 2017-06-21
Primary completion date: 2020-03-30
Completion date: 2020-03-30
Plan to share individual participant data: NO
Clinical trial NCT04265755: Biomarker and Genetic Predictors of Erenumab Treatment Response
Official title: Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE)
Acronym: INTERROGATE
Sponsor: Amgen (INDUSTRY)
Study type: INTERVENTIONAL
Phase: PHASE4
Status: COMPLETED 
Enrollment: 1406.0 (ACTUAL)
Number of arms: 1.0
Start date: 2020-10-26
Primary completion date: 2023-01-18
Completion date: 2023-01-18
Baseline population: Full Analysis Set (FAS): consisted of all participants who were enrolled in the study.
Plan to share individual participant data: NO
IPD sharing description: There is not a plan to make IPD available